Analysts Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $16.60

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) have received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $16.60.

Several research analysts have weighed in on the stock. Guggenheim decreased their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. William Blair initiated coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Wedbush lifted their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Vigil Neuroscience in the second quarter worth $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience in the 2nd quarter worth about $87,000. Renaissance Technologies LLC lifted its position in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares during the last quarter. Walleye Capital LLC boosted its stake in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the period. Finally, Verition Fund Management LLC bought a new position in Vigil Neuroscience in the 3rd quarter worth about $442,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Trading Down 0.9 %

Vigil Neuroscience stock opened at $2.25 on Wednesday. The stock has a 50 day moving average of $3.29 and a 200-day moving average of $3.58. The stock has a market cap of $91.98 million, a P/E ratio of -1.09 and a beta of 1.66. Vigil Neuroscience has a 52 week low of $2.08 and a 52 week high of $6.06.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.